Miltefosine for new world cutaneous leishmaniasis.
The oral agent miltefosine has demonstrated a >95% cure rate in Indian visceral leishmaniasis. We performed a large, placebo-controlled study of miltefosine therapy (2.5 mg/kg per day orally for 28 days) against cutaneous leishmaniasis in Colombia and Guatemala. In regions in Colombia where Leishmania vianna panamensis is common, the per-protocol cure rates for miltefosine and placebo were 91% (40 of 44 patients) and 38% (9 of 24). These values are similar to historic values for the antimony standard of care and placebo. In regions in Guatemala where L. v. braziliensis and L. mexicana mexicana are common, the per-protocol cure rates were 53% (20 of 38) for miltefosine and 21% (4 of 19) for placebo. The miltefosine rate was lower than historic antimony cure rates of >90%. Miltefosine was well tolerated. Miltefosine is a useful oral agent against cutaneous leishmaniasis due to L. v. panamensis in Colombia but not against leishmaniasis due to L. v. braziliensis in Guatemala.
Soto
J
J
Consorcio de Investigaciones Bioclinicas, Bogotá, Colombia.
Arana
B A
BA
Toledo
J
J
Rizzo
N
N
Vega
J C
JC
Diaz
A
A
Luz
M
M
Gutierrez
P
P
Arboleda
M
M
Berman
J D
JD
Junge
K
K
Engel
J
J
Sindermann
H
H
D000284:Administration, Oral; D000328:Adult; D000818:Animals; D000981:Antiprotozoal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003105:Colombia; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006166:Guatemala; D006801:Humans; D007891:Leishmania / Q000187:drug effects; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D010349:Patient Compliance; D010767:Phosphorylcholine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016896:Treatment Outcome
D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine